Enzon Pharmaceuticals, Inc. (ENZN)
| Market Cap | 7.70M |
| Revenue (ttm) | 26.00K |
| Net Income (ttm) | -497.00K |
| Shares Out | 74.21M |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,000 |
| Average Volume | 32,902 |
| Open | 0.1050 |
| Previous Close | 0.1050 |
| Day's Range | 0.1050 - 0.1050 |
| 52-Week Range | 0.0600 - 0.2400 |
| Beta | 0.26 |
| RSI | 45.81 |
| Earnings Date | Mar 21, 2025 |
About Enzon Pharmaceuticals
Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, it sells its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey. [Read more]
Financial Performance
Financial StatementsNews
Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon's CFO, to Assume Position of CEO and Remain CFO
CRANFORD, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the Com...
Enzon Pharmaceuticals Announces Results of Rights Offering
Looking to Next Step – Acquisition Opportunities Looking to Next Step – Acquisition Opportunities
Enzon Pharmaceuticals Announces Key Dates for Rights Offering
CRANFORD, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) announced today the record date and expected subscription period for its previous...
Enzon Pharmaceuticals, Inc. Announces Postponement of 2020 Annual Meeting
CRANFORD, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its 2020 annual meeting of stockholders (the “Annual Meeting...
Enzon Pharmaceuticals Anticipated Rights Offering to Existing Shareholders
CRANFORD, N.J., Aug. 21, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC: ENZN) today announced that its Board of Directors (the “Board”) has approved a rights o...
Enzon Pharmaceuticals, Inc. Adopts Tax Benefits Preservation Plan to Protect its NOL Assets and Shareholder Value
CRANFORD, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its Board of Directors (the “Board”) adopted a tax benefits p...
Bullish On Enzon And Sesen From Different Perspectives
ENZN trades at all time highs, adjusted for dividends, and double the "base case" of the liquidation value.
Enzon Pharmaceuticals - Heads Equals Royalties, Tails Equals Cash
Trading for less than its liquid book value.